Jump to main content
Jump to site search

All chapters
Previous chapter Next chapter

CHAPTER 12

Designing an Effective Peptide Vaccine

The traditional strategy for producing prophylactic vaccines from live-attenuated or inactivated microorganisms, and more recently from a subset of the pathogen’s proteins, is unsuitable in certain cases, due to safety issues and/or unproductive or even detrimental immune responses. An alternative strategy is to focus the immune response towards only the minimal peptide epitopes that are the target of the protective response. In parallel, therapeutic peptide vaccines are being developed for conditions such as cancer, allergy and autoimmune diseases. Although no peptide vaccine has yet been approved for human therapy, considerable progress has been made in understanding the rules of design for such a vaccine.

Publication details


Print publication date
26 Jun 2017
Copyright year
2017
Print ISBN
978-1-78262-732-6
PDF eISBN
978-1-78801-153-2
ePub eISBN
978-1-78801-171-6
From the book series:
Drug Discovery